TerminatedNot Applicable

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Stopped: Sponsor Decision - Low Enrollment

United States2 participantsStarted 2022-04-14

Plain-language summary

This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) to compare the visual outcomes of AU-011 and plaque radiotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Have per the investigator's expert clinical judgment, a clinical diagnosis of primary indeterminate lesion or choroidal melanoma based on the clinical history, ophthalmic examination, fundus photography and conventional ocular ultrasound.

What they're measuring

Visual Acuity

Timeframe: 5 years

Trial details

NCT IDNCT05266430

SponsorAura Biosciences

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-02-01

View on ClinicalTrials.gov More Choroidal Melanoma trials